Michigan Builds MRI Tools to Screen Alzheimer's Treatments
Researchers at the Michigan Alzheimer's Disease Research Center are developing imaging methods to better select patients for newer Alzheimer's drugs and monitor side effects.
Updated on Nov. 15, 2026 in Diseases

Live Poll
Do you think access to Alzheimer's diagnosis in your area is getting better?
The Michigan Alzheimer's Disease Research Center, which combines professionals from the University of Michigan, Michigan State University and Wayne State University, is developing MRI tools to better screen candidates for Alzheimer's treatment and monitor possible side effects. Michigan ranks eighth in the country for Alzheimer's disease deaths.
Why it matters
Lecanemab and donanemab, marketed as Leqembi and Kisunla, are IV infusions for Alzheimer's that require careful patient selection and monitoring. Better imaging tools could help clinicians in Michigan decide which patients are candidates for these treatments and watch for adverse effects.
Michigan ranks eighth in the country for Alzheimer's disease deaths, a ranking that frames the state's stake in better diagnosis and treatment selection. The extraction does not specify how many Michigan residents are affected or when the new MRI screening tools will be validated.
The players
BAMF Health
BAMF Health is a Grand Rapids-based health provider whose PET/MR scanner evaluates dementia progression in a single visit.
Michigan Alzheimer's Disease Research Center
The center brings together researchers from the University of Michigan, Michigan State University and Wayne State University to study Alzheimer's disease and its treatment.
The details
The Michigan Alzheimer's Disease Research Center is developing MRI tools to screen candidates for Alzheimer's treatment and track possible side effects. Locally, BAMF Health in Grand Rapids is the only Michigan site able to perform a brain MRI and amyloid PET scan in a single visit, measuring amyloid plaque buildup and a patient's stage of dementia progression.
Timeline
2023: The FDA approved the first of two Alzheimer's IV drugs, lecanemab.
2024: The FDA approved the second Alzheimer's IV drug, donanemab.
Health Landscape
The Michigan Alzheimer's Disease Research Center's collaboration among three state universities extends a research model focused on screening patients for newer IV Alzheimer's drugs, lecanemab and donanemab, approved in 2023 and 2024. This places the center's imaging work within the broader effort to match patients to these therapies safely.
For Michigan patients and families, the research points toward more precise screening before IV Alzheimer's infusions and closer monitoring for side effects. Patients considering these treatments may find that brain imaging, including single-visit MRI and amyloid PET scans, becomes a more available part of their evaluation.
The takeaway
Michigan's imaging research aims to make Alzheimer's IV treatments safer to start and easier to monitor. Patients and families should ask their clinicians whether brain imaging is part of evaluating candidacy for these drugs.
Further reading
For more on the disease itself, see our Alzheimer’s coverage.
Source note: This article includes information reported by Thealpenanews.
Live Poll
Do you think access to Alzheimer's diagnosis in your area is getting better?






